Table 2 Patient characteristics and outcome
No. | Gender | History | PRS-type | Prior therapy | Dose of bevacizumab | Dose of TMZ | Dose of Sintilimab | Using period | Best response | PFS(months) | DOR(months) |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | GBM | Primary | Surgery | 200(3) 500(2) | 160 | 200 | 5 | PR | 3.29 | 1.84 |
2 | M | GBM | secondary | NA | 500 | 240 | 200 | 4 | PR | 2.70 | 1.27 |
3 | M | GBM | Primary | Bevacizumab | 500 | 300 | 200 | 8 | PR | 6.10 | 5.16 |
4 | F | GBM | Primary | Bevacizumab | 600 | 300 | 200 | 4 | SD | 4.10 | |
5 | M | GBM | Primary | GNC−039 | 500 | 300 | 200 | 7 | SD | 5.10 | |
6 | F | GBM | Primary | NA | 500 | 260 | 200 | 10 | PR | 8.52+ | 6.57+ |
7 | F | GBM | Primary | GNC−039 | 500 | 240 | 200 | 5 | PR | 3.34 | 1.58 |
8 | F | GBM | secondary | NA | 600 | 240 | 200 | 3 | PD | 1.45 |